ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1045

Quantification of the Enthesic Response to Biological Therapies in Patients with Spondyloarthritis by Computer Analysis of Ultrasound Images

Marina Tortosa Cabanas, CARLOS ANTONIO GUILLEN ASTETE and Africa Andreu Suarez, Ramon y Cajal University Hospital, Madrid, Spain

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), Biologicals, Psoriatic arthritis, spondyloarthritis, Ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Treatment Poster II: Mixed

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Enthesitis is the base of the pathophysiology of spondyloarthritis. Recently, our research group has shown that computer analysis of static images can be used in the evaluation of patients with enthesic inflammatory diseases with good intra-patient and intra-observer validity and sensitivity to change.

The purpose of this study is to determine the enthesic evolution in patients with spondyloarthritis (SpA) treated with three different biological therapies through the computer analysis of ultrasound images.

Methods: We selected patients diagnosed with SpA and enthesitis followed by imaging, who started biological therapy with a TNF inhibitor, an IL17 inhibitor or an IL12/23 inhibitor. For the records to be included, it was necessary to have clinical information from the period of perfoming the ultrasound. All images were obtained from the Achilles tendon, with the same ultrasound equipment, grayscale and settings for each patient.

To homogenize the results of the analysis, the gray intensity mean index (iMIG) was used. It is defined as mean gray intensity in the clinically affected enthesis/mean gray intensity in the same healthy enthesis. It has been shown to appropriately discriminate the inflammatory pathology from the mechanical or healthy controls as well as being sensitive to change.

Results: 14 patients were included: 6 treated with a TNF inhibitor, 4 with an IL17 inhibitor and 4 with an IL12/23 inhibitor. Patients 2, 3, 5, 7, 10, 11, and 12 had enthesophytes.

In the global analysis, the iMIG did not show statistically significant differences between the treatment groups at the start of the treatment, at the intermediate and at the final evaluation (P=.588, .739 and .674, respectively).

Patients with enthesophytes presented significantly higher baseline, intermediate and final iMIG than patients without them: 1.26 SD 0.14 vs 0.85 SD 0.05 (t=7.407, P=.001), 1.24 SD 0.15 vs 0.97 SD 0.1 (t=3.659, P=.006); and 1.21 SD 0.12 vs 1.05 SD 0.07 (t=2.342, P=.037), respectively.

Analyzing only the patients without enthesophytosis, the final iMIG showed statistically significant differences between the 3 administered treatments (ANOVA, F=8.142, P=.027), being relevant between the use of IL12/23 and TNF inhibitor in favor of the former (Bonferroni, P=.03).

In the same subgroup of patients without enthesophytosis, iMIG analysis over time showed statistically significant differences between final and baseline iMIG (Friedman -1.938 P=.000).

Conclusion: Computer analysis of ultrasound images using the iMIG distinguishes therapeutic response in patients without enthesophytosis.

The interposition of enthesophytes impede the correct visualization of the enthesis and does not allow ultrasound changes to be detected in some areas of the image.

Although there are indications that the use of this analysis could also predict the behavior of certain therapies, it is convenient to propose prospective studies with homogeneous ultrasound controls.

Supporting image 1

Table 1: List of patients included in the analysis. After the final ultrasound examination, the follow-up time up to the present is recorded in the case of continued treatment (m: months).


Disclosures: M. Tortosa Cabanas, UCB; C. GUILLEN ASTETE, Novartis, Janssen; A. Andreu Suarez, None.

To cite this abstract in AMA style:

Tortosa Cabanas M, GUILLEN ASTETE C, Andreu Suarez A. Quantification of the Enthesic Response to Biological Therapies in Patients with Spondyloarthritis by Computer Analysis of Ultrasound Images [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/quantification-of-the-enthesic-response-to-biological-therapies-in-patients-with-spondyloarthritis-by-computer-analysis-of-ultrasound-images/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/quantification-of-the-enthesic-response-to-biological-therapies-in-patients-with-spondyloarthritis-by-computer-analysis-of-ultrasound-images/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology